Glucose and glucose degradation products (GDPs) in peritoneal dialysis fluids (PDFs) are both thought to mediate progressive peritoneal worsening.
Methods
In a multicenter, prospective, randomized crossover study, incident continuous ambulatory peritoneal dialysis patients were treated either with conventional lactate-buffered PDF (sPD regimen) or with a regimen low in glucose and GDPs: Nutrinealx1, Extranealx1, and Physionealx2 (NEPP regimen; all solutions: Baxter Healthcare, Utrecht, Netherlands). After 6 months, patients were switched to the alternative regimen for another 6 months. After 6 weeks of run-in, before the switch, and at the end of the study, 4-hour peritoneal equilibration tests were performed, and overnight effluents were analyzed for cells and biomarkers. Differences between the regimens were assessed by multivariate analysis corrected for time and regimen sequence.
Results
The 45 patients who completed the study were equally distributed over both groups. During NEPP treatment, D4/D0 glucose was lower (p < 0.01) and D/P creatinine was higher (p = 0.04). In NEPP overnight effluent, mesothelial cells (p < 0.0001), cancer antigen 125 (p < 0.0001), hyaluronan (p < 0.0001), leukocytes (p < 0.001), interleukins 6 (p = 0.001) and 8 (p = 0.0001), and vascular endothelial growth factor (VEGF, p < 0.0001) were increased by a factor of 2 – 3 compared with levels in sPD effluent. The NEPP regimen was associated with higher transport parameters, but that association disappeared after the addition of VEGF to the model. The association between NEPP and higher effluent levels of VEGF could not be attributed to glucose and GDP loads.
Conclusions
Study results indicate preservation of the mesothelium and increased peritoneal activation during NEPP treatment. Whether the increase in VEGF reflects an increase in mesothelial cell mass or whether it points to another, undesirable mechanism cannot be determined from the present study. Longitudinal studies are needed to finally evaluate the usefulness of the NEPP regimen for further clinical use.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
6.
ZareieM., HekkingL.H., WeltenA.G., DriesprongB.A., Schadee-EestermansI.L., FaictD.Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo.Nephrol Dial Transplant2003; 18: 2629–37.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
9.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
VisserC.E., Brouwer-SteenbergenJ.J., BetjesM.G., KoomenG.C., BeelenR.H., KredietR.T.Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
12.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
13.
HekkingL.H., ZareieM., DriesprongB.A., FaictD., WeltenA.G., de GreeuwI.Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate–buffered solution.J Am Soc Nephrol2001; 12: 2775–86.
14.
PosthumaN., VerbrughH.A., DonkerA.J., van DorpW., DekkerH.A., PeersE.M.Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years.Perit Dial Int2000; 20: 174–80.
15.
TaylorG.S., PatelV., SpencerS., FluckR.J., McIntyreC.W.Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients.Clin Nephrol2002; 58: 445–50.
16.
le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.Adv Perit Dial2004; 20: 170–6.
17.
le PooleC.Y., WeltenA.G., WeijmerM.C., ValentijnR.M., van IttersumF.J., ter WeeP.M.Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.Perit Dial Int2005; 25(Suppl 3): S64–8.
BetjesM.G., TukC.W., StruijkD.G., KredietR.T., AriszL., HoefsmitE.C.Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study.Kidney Int1993; 43: 641–8.
20.
TekstraJ., VisserC.E., TukC.W., Brouwer-SteenbergenJ.J., BurgerC.W., KredietR.T.Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients.J Am Soc Nephrol1996; 7: 2379–84.
21.
FosangA.J., HeyN.J., CarneyS.L., HardinghamT.E.An ELISA plate-based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding region).Matrix1990; 10: 306–13.
22.
Kumar-SinghS., JacobsW., DhaeneK., WeynB., BogersJ., WeylerJ.Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.J Pathol1998; 186: 300–5.
23.
GulyásM., HjerpeA.Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.J Pathol2003; 199: 479–87.
24.
SubramanianS.V., FitzgeraldM.L., BernfieldM.Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation.J Biol Chem1997; 272: 14713–20.
25.
FitzgeraldM.L., WangZ., ParkP.W., MurphyG., BernfieldM.Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3–sensitive metalloproteinase.J Cell Biol2000; 148: 811–24.
26.
MartisL., PatelM., GiertychJ., MongovenJ., TaminneM., PerrierM.A.Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution.Lancet2005; 365: 588–94.
27.
BoerW.H., VosP.F., FierenM.W.Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis.Perit Dial Int2003; 23: 33–8.
28.
TwiskJ.W.Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis.Eur J Epidemiol2004; 19: 769–76.
29.
JohnsonD.W., MudgeD.W., BlizzardS., ArndtM., O'SheaA., WattR.A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement.Perit Dial Int2004; 24: 460–5.
30.
KredietR.T.Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.Perit Dial Int2001; 21: 560–7.
31.
DayR.M., MitchellT.J., KnightS.C., ForbesA.Regulation of epithelial syndecan-1 expression by inflammatory cytokines.Cytokine2003; 21: 224–33.
32.
LaiK.N., SzetoC.C., LaiK.B., LamC.W., ChanD.T., LeungJ.C.Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD.Am J Kidney Dis1999; 33: 318–24.
33.
YungS., ThomasG.J., DaviesM.Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro.Kidney Int2000; 58: 1953–62.
34.
HoriuchiT., MiyamotoK., MiyamotoS., FujitaM., SanoN., MinamiyamaK.Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: the role of hyaluronan synthesis.Kidney Int2003; 64: 2280–90.
35.
RosengrenB.I., CarlssonO., RippeB.Hyaluronan and peritoneal ultrafiltration: a test of the “filter-cake” hypothesis.Am J Kidney Dis2001; 37: 1277–85.
WitowskiJ., WisniewskaJ., KorybalskaK., BenderT.O., BreborowiczA., GahlG.M.Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.J Am Soc Nephrol2001; 12: 2434–41.
38.
BajoM.A., SelgasR., CastroM.A., del PesoG., DiazC., Sánchez– TomeroJ.A.Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo.Perit Dial Int2000; 20: 742–7.
39.
ZareieM., van LambalgenA.A., ter WeeP.M., HekkingL.H., KeuningE.D., Schadee-EestermansI.L.Better preservation of the peritoneum in rats exposed to amino acid–based peritoneal dialysis fluid.Perit Dial Int2005; 25: 58–67.
40.
QuagliaroL., PiconiL., AssaloniR., MartinelliL., MotzE., CerielloA.Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P) H-oxidase activation.Diabetes2003; 52: 2795–804.
41.
ParikovaA., ZweersM.M., StruijkD.G., KredietR.T.Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.Adv Perit Dial2003; 19: 186–90.
42.
MartikainenT.A., TeppoA.M., Grönhagen-RiskaC., EkstrandA.V.Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?Perit Dial Int2005; 25: 453–60.
43.
PosthumaN., ter WeeP.M., VerbrughH.A., OeP.L., PeersE., SayersJ.Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance.Nephrol Dial Transplant1997; 12: 550–3.
44.
MoriishiM., KawanishiH., WatanabeH., TsuchiyaS.Correlation between peritoneal permeability and ultrafiltration volume with icodextrin-based peritoneal dialysis solution.Adv Perit Dial2004; 20: 166–9.
